HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by Tahan, F. Articles by Koc, N. Search for Related Content PubMed PubMed Citation Articles by Tahan, F. Articles by Koc, N.

Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial

¹ Depts of Paediatric Allergy, ² Paediatrics, and ³ Microbiology, Erciyes University School of Medicine, Kayseri, Turkey.

CORRESPONDENCE: F. Tahan, Dept of Paediatric Allergy, Erciyes University School of Medicine, Kayseri 38039, Turkey. Fax: 90 3524375825. E-mail: tahanfulya{at}yahoo.com

Keywords: Bronchiolitis, clarithromycin, eotaxin, interleukin-4, interleukin-8, respiratory syncytial virus

Received: February 27, 2006
Accepted August 29, 2006

Respiratory syncytial virus (RSV) bronchiolitis is the most common lower respiratory tract infection in infancy. To date, there is no effective therapy for RSV bronchiolitis.

In order to investigate the efficacy of clarithromycin in the treatment of RSV bronchiolitis, the present authors conducted a randomised, double-blind, placebo-controlled trial comparing clarithromycin with placebo in 21 infants with a diagnosis of RSV bronchiolitis. The infants were randomised to receive clarithromycin or placebo daily for 3 weeks. Levels of interleukin (IL)-4, IL-8, eotaxin, and interferon- were determined in plasma, before and after treatment, using ELISA. Six months after treatment, parents were surveyed as to whether their child had experienced wheezing within the previous 6 months.

Treatment with clarithromycin was associated with a statistically significant reduction in the length of hospital stay, the duration of need for supplemental oxygen and the need for ß₂-agonist treatment. There were significant decreases in plasma IL-4, IL-8 and eotaxin levels after 3 weeks of treatment with clarithromycin. Readmission to the hospital within 6 months after discharge was significantly lower in the clarithromycin group.

In conclusion, clarithromycin has statistically significant effects on the clinical and laboratory findings in respiratory syncytial virus bronchiolitis. Therefore, clarithromycin treatment may be helpful in reducing the short-term effects of respiratory syncytial virus bronchiolitis.

This article has been cited by other articles:

				J. L. Simpson, H. Powell, M. J. Boyle, R. J. Scott, and P. G. Gibson Clarithromycin Targets Neutrophilic Airway Inflammation in Refractory Asthma Am. J. Respir. Crit. Care Med., January 15, 2008; 177(2): 148 - 155. [Abstract] [Full Text] [PDF]

				M. S. L. Shell, C. W. Calabria, G. L. Casoni, V. Poletti, P. Stafler, H. M. Corneli, J. J. Zorc, and N. Kuppermann Dexamethasone for Bronchiolitis N. Engl. J. Med., October 18, 2007; 357(16): 1659 - 1660. [Full Text] [PDF]

				M. Korppi Macrolides and bronchiolitis in infants Eur. Respir. J., June 1, 2007; 29(6): 1283 - 1284. [Full Text] [PDF]

				F. Tahan From the authors Eur. Respir. J., June 1, 2007; 29(6): 1284 - 1285. [Full Text] [PDF]

				M. C. J. Kneyber and J. L. L. Kimpen Antibiotics in RSV bronchiolitis: still no evidence of effect Eur. Respir. J., June 1, 2007; 29(6): 1285 - 1285. [Full Text] [PDF]